POSITIONS OF CALCIUM CHANNEL BLOCKER LERCANIDIPINE ACCORDING TO EVIDENCE BASED CARDIOLOGY

Abstract

Data of evidence based cardiology including results of international clinical trials on efficacy and safety of the modern calcium channel blocker (CCB), lercanidipine, are presented. Results of these trials show the firm position of lercanidipine in the modern cardiology and confirm that treatment with lercanidipine leads to significant reduction of systolic and diastolic blood pressure (BP) with no effect on heart rate (HR). Peripheral edema (the common side effect of CCBs) occurs rarer with lercanidipine treatment than this with any other CCB treatment. Lercanidipine can be recommended to patients with concomitant diseases due to its additional features.

Keywords

• lercanidipine
• calcium channel blockers
• randomized clinical trials
• arterial hypertension